Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 889-895

  Hussein, Mohamad A ^a   Baz, Rachid ^a   Srkalovic, Gordan ^b   Agrawal, Neeraj ^c   Suppiah, Revathi ^a   Hsi, Eric ^a   Andresen, Steven ^a   Karam, Mary Ann ^a   Reed, Janice ^a   Faiman, Beth ^a   Kelly, Megan ^a   Walker, Esteban ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Division of Pediatric Surgery   (United States)

^c Cancer Centers of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HAND FOOT SYNDROME; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUSCLE CRAMP; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREMOR;

EID: 33745628076     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.889     Document Type: Article

References (28)

1. Jemal A, Tiwari RC, Murray T, et al, American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist. 2003;8(suppl):39-45.
3. Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: 2465-2499.
4. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004 May 15;22:1857-1863. Epub 2004 Apr 26.
5. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
6. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882-885.
7. Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002; 95:2160-2168.
8. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006;106:848-858.
9. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98:492-494.
10. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
11. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
12. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
13. Hussein MA. Thalidomide: present and future in multiple myeloma. Expert Rev Anticancer Ther. 2005;5:25-31.
14. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712-3720.
15. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104-1112.
16. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
17. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
18. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
19. Kelly D, Wischmeyer PE. Role of L-glutamine in critical illness: new insights. Curr Opin Clin Nutr Metab Care. 2003;6:217-222.
20. Tapiero H, Mathe G, Couvreur P, Tew KD. II: glutamine and glutamate. Biomed Pharmacother. 2002;56:446-457.
21. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ, Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003; 122:441-450.
22. 12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer. 2004;101:790-795.
23. Blade J, Samson D, Reece D, et al, Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
24. Attal M, Harousseau JL, Stoppa AM, et al, Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335: 91-97.
25. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501-2507.
26. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568-1574.
27. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16: 3832-3842.
28. Attal M, Harousseau JL, Facon T, et al, InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma [published correction appears in N Engl J Med. 2004;350:2628]. N Engl J Med. 2003;349:2495-2502.